SELLAS Life Sciences Group, Inc.
SLS
$1.41
$0.010.71%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.27% | -16.38% | -22.13% | 10.40% | -14.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.94% | -21.71% | -15.79% | -14.50% | -13.43% |
| Operating Income | 1.94% | 21.71% | 15.79% | 14.50% | 13.43% |
| Income Before Tax | 17.20% | 23.30% | 15.50% | 13.80% | 10.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.20% | 23.30% | 15.50% | 13.80% | 10.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.20% | 23.30% | 15.50% | 13.80% | 10.80% |
| EBIT | 1.94% | 21.71% | 15.79% | 14.50% | 13.43% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 65.51% | 68.15% | 58.43% | 54.70% | 39.81% |
| Normalized Basic EPS | 59.90% | 68.14% | 58.44% | 54.70% | 40.91% |
| EPS Diluted | 65.51% | 68.15% | 58.31% | 54.70% | 39.81% |
| Normalized Diluted EPS | 59.90% | 68.14% | 58.44% | 54.70% | 40.91% |
| Average Basic Shares Outstanding | 140.18% | 140.71% | 103.30% | 90.31% | 48.21% |
| Average Diluted Shares Outstanding | 140.18% | 140.71% | 103.30% | 90.31% | 48.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |